Catalpol’s unique action on multiple angiogenic pathways, including β-catenin, HIF-1α, VEGF, and angiopoietin-2, and on inflammatory biomarkers (i.e., MCP-1) suggests that these mechanisms may play key roles in treating retinal ischemia. This evidence concerns the gene CCL2 and retinal ischemia.